Questionnaire to Measure Abdominal Symptoms in Cystic Fibrosis
Develops and tests a new questionnaire on belly symptoms in people with cystic fibrosis.
Plain-language title generated from the registry record
Registry title: Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)
Key facts
- Where
- Brandenburg an der Havel, GermanySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cystic fibrosis, and for healthy people of a similar age, to test a new questionnaire about belly symptoms.
- Sex
- All sexes can join.
- Disease stage
- Cystic fibrosis confirmed by a sweat chloride above 60 mEq/L, or by 2 disease-causing CFTR mutations with signs of organ involvement.
- Biomarker or test result
- Sweat chloride above 60 mEq/L, or 2 disease-causing CFTR mutations.
Main reasons for not taking part
- People with cystic fibrosis who cannot cooperate (or whose families cannot) cannot join.
- Healthy controls with other diseases that cause belly symptoms cannot join, such as inflammatory bowel disease, alpha 1 antitrypsin deficiency, celiac disease, food allergy or gastroenteritis.
Read by machine on 9 November 2026.
Where in Germany
- Klinikum WestbrandenburgBrandenburg an der Havel, GermanyTaking people
- Medizinische Hochschule Brandenburg (MHB), UniversityBrandenburg an der Havel, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medizinische Hochschule Brandenburg Theodor Fontane
- Trial code
- NCT03052283
- Record updated
- 4 April 2023
- Original description
Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.Read full original descriptionShow less
Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)
Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.
In the stepwhise development of the patient reported outcome measures (PROM) repeadedly, CF-patients, their families as well as professionals working in different fields of CF-care will be included.
Inclusion: CF cohort:; Diagnosis of CF determined by; a sweat chloride of >60 mEq/L and/or; detection of 2 disease causing CFTR mutations with evidence of organ involvement; Healthy controls:; Age-matched.
Exclusion: Other diseases causing abdominal symptoms (Inflammatory bowel disease (IBD), alpha 1 antitrypsin deficiency, celiac disease, food allergy, gastroenteritis, etc.); CF cohort:; Lacking ability to cooperate of patients /their families, respectively; Healthy controls:.